α1抗トリプシン薬の世界市場

α1抗トリプシン薬の世界市場は2030年までに45億米ドルに達する見込み

2023年に23億米ドルと推定されるα1抗トリプシン薬の世界市場は、分析期間2023-2030年にCAGR 9.6%で成長し、2030年には45億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるプロラスチンCドラッグは、CAGR 9.4%を記録し、分析期間終了時には21億米ドルに達すると予測されます。グラシア医薬品セグメントの成長率は、分析期間中CAGR 10.4%と推定されます。

米国市場は6億5,110万米ドルと推定、中国はCAGR9.0％で成長予測

米国のα1抗トリプシン薬市場は、2023年に6億5,110万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 9.0%で推移し、2030年には6億7,980万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.9%と7.9%と予測されています。欧州では、ドイツがCAGR 7.8%で成長すると予測されています。

世界のα1抗トリプシン薬市場- 主要動向と促進要因まとめ

α1アンチトリプシン欠乏症とは何か、なぜ薬が必要なのか？

α1アンチトリプシン（AAT）欠乏症は、重篤な呼吸器疾患や肝疾患を引き起こす可能性のある遺伝性疾患です。この疾患は、感染症やタバコの煙のような刺激物による炎症から肺を保護する、肝臓で産生されるタンパク質であるα-1アンチトリプシンの欠乏から生じます。AAT欠損症の患者は、慢性閉塞性肺疾患（COPD）、肺気腫、肝硬変や肝がんなどの肝疾患を発症するリスクが高いです。未治療のAAT欠損症は患者のQOLに深刻な影響を与え、余命を縮める可能性があるため、効果的な治療薬の必要性は極めて重要です。現在の治療法は、欠乏したタンパク質を補い、病気の進行を遅らせ、症状を管理することで、全体的な健康状態を改善することを目的としています。

技術の進歩はα1抗トリプシン薬の開発にどのような影響を与えているか？

技術の進歩はα1抗トリプシン薬の開発に大きな影響を与え、その有効性と送達を向上させています。吸入可能な治療薬や高度な点滴法などのドラッグデリバリーシステムの革新は、治療の利便性と有効性を向上させ、患者が服薬レジメンを守りやすくしました。さらに、遺伝子および分子研究の飛躍的進歩により、遺伝子治療や組換えDNA技術などの新しい治療法への道が開かれ、より的を絞った長期にわたる治療が可能になった。こうした進歩は、患者の予後を改善するだけでなく、投与頻度や関連するヘルスケアコストを削減し、患者にとって治療がより身近で管理しやすいものとなっています。

どのような動向がα1抗トリプシン薬の需要を牽引していますか？

いくつかの動向がα1抗トリプシン薬の需要増加を促進しています。意識の高まりと診断技術の向上により、AAT欠損症がより早く正確に発見され、タイムリーな治療開始につながっています。また、肺疾患や肝疾患の治療におけるAAT製剤の用途が拡大していることも、需要の拡大に寄与しています。さらに、規制当局の承認や革新的治療への支援により、市場での新たな治療法の利用が加速しています。製薬企業による研究開発への投資の増加は、治療選択肢の改善と拡大に対する継続的なコミットメントを浮き彫りにしています。さらに、患者擁護団体や支援団体の増加は、AAT欠損症について一般市民やヘルスケアプロバイダーを教育する上で重要な役割を果たしており、効果的な治療法に対する需要をさらに押し上げています。

α1抗トリプシン薬市場の成長を促進している要因は？

α1抗トリプシン薬市場の成長は、主に技術的進歩、治療用途の拡大、進化するヘルスケアランドスケープなど、いくつかの要因によって牽引されています。ドラッグ開発やデリバリーシステムにおける技術革新は、AAT療法の有効性と利便性を大幅に向上させ、患者やヘルスケアプロバイダーにとってより魅力的なものとなっています。肺疾患や肝疾患における治療用途の拡大は市場を拡大し、医薬品メーカーに新たな機会をもたらしています。さらに、新興市場における医療費の増加や診断能力の向上など、市場情勢の進化がAAT療法の幅広い採用を促進しています。製薬企業と研究機関の戦略的提携により、新規かつ革新的な治療法の開発が加速しています。さらに、規制当局の支援と個別化医療の台頭が、個々の患者のニーズに合わせたカスタムメイドのAAT療法の採用を後押ししており、今後数年間の市場の堅調な成長軌道を確実なものにしています。

調査対象企業の例（注目の43社）

• Abeona Therapeutics
• Alnylam Pharmaceuticals
• Applied Genetic Technologies Corp
• Arrowhead Research Corporation
• Baxalta
• Baxter
• CSL Behring
• Grifols
• Kamada
• Shire
• Takeda Pharmaceutical Company Limited

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Alpha-1 Antitrypsin Drugs Market to Reach US$4.5 Billion by 2030

The global market for Alpha-1 Antitrypsin Drugs estimated at US$2.3 Billion in the year 2023, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 9.6% over the analysis period 2023-2030. Prolastin C Drug, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Glassia Drug segment is estimated at 10.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$651.1 Million While China is Forecast to Grow at 9.0% CAGR

The Alpha-1 Antitrypsin Drugs market in the U.S. is estimated at US$651.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$679.8 Million by the year 2030 trailing a CAGR of 9.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Global Alpha-1 Antitrypsin Drugs Market - Key Trends and Drivers Summarized

What Is Alpha-1 Antitrypsin Deficiency and Why Are Drugs Needed?

Alpha-1 Antitrypsin (AAT) deficiency is a genetic disorder that can lead to severe respiratory and liver diseases. This condition results from a lack of alpha-1 antitrypsin, a protein produced by the liver that protects the lungs from inflammation caused by infection or irritants like tobacco smoke. Individuals with AAT deficiency are at a higher risk of developing chronic obstructive pulmonary disease (COPD), emphysema, and liver diseases such as cirrhosis and liver cancer. The need for effective drugs is critical, as untreated AAT deficiency can severely impact a patient's quality of life and reduce life expectancy. Current treatments aim to supplement the deficient protein, slow disease progression, and manage symptoms to improve overall health outcomes.

How Are Technological Advancements Influencing Alpha-1 Antitrypsin Drug Development?

Technological advancements have significantly influenced the development of Alpha-1 Antitrypsin drugs, enhancing their efficacy and delivery. Innovations in drug delivery systems, such as inhalable therapies and advanced infusion methods, have improved the convenience and effectiveness of treatment, making it easier for patients to adhere to their medication regimens. Additionally, breakthroughs in genetic and molecular research have paved the way for novel therapies, including gene therapy and recombinant DNA technology, which offer the potential for more targeted and long-lasting treatments. These advancements not only improve patient outcomes but also reduce the frequency of administration and associated healthcare costs, making treatment more accessible and manageable for patients.

What Trends Are Driving the Demand for Alpha-1 Antitrypsin Drugs?

Several trends are driving the increasing demand for Alpha-1 Antitrypsin drugs. Rising awareness and improved diagnostic techniques have led to earlier and more accurate detection of AAT deficiency, resulting in timely treatment initiation. The expanding applications of AAT drugs in treating a broader range of pulmonary and hepatic diseases have also contributed to their growing demand. Moreover, regulatory approvals and support for innovative therapies have accelerated the availability of new treatments in the market. The increasing investment in research and development by pharmaceutical companies highlights the ongoing commitment to improving and expanding treatment options. Furthermore, the growing number of patient advocacy and support groups plays a crucial role in educating the public and healthcare providers about AAT deficiency, driving further demand for effective treatments.

What Factors Are Propelling the Growth of the Alpha-1 Antitrypsin Drugs Market?

The growth in the Alpha-1 Antitrypsin drugs market is driven by several factors, primarily technological advancements, expanding therapeutic applications, and evolving healthcare landscapes. Technological innovations in drug development and delivery systems have significantly enhanced the efficacy and convenience of AAT therapies, making them more attractive to patients and healthcare providers. Expanding therapeutic applications in pulmonary and hepatic diseases have broadened the market, creating new opportunities for drug manufacturers. Additionally, evolving healthcare landscapes, including increased healthcare expenditure and better diagnostic capabilities in emerging markets, have facilitated wider adoption of AAT therapies. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the development of new and innovative treatments. Furthermore, regulatory support and the rise of personalized medicine are driving the adoption of customized AAT therapies tailored to individual patient needs, ensuring a robust growth trajectory for the market in the coming years.

Select Competitors (Total 43 Featured) -

• Abeona Therapeutics
• Alnylam Pharmaceuticals
• Applied Genetic Technologies Corp
• Arrowhead Research Corporation
• Baxalta
• Baxter
• CSL Behring
• Grifols
• Kamada
• Shire
• Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Alpha-1 Antitrypsin Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Alpha-1 Antitrypsin Deficiency Propels Demand for Treatment
  • Rising Awareness and Diagnosis Rates Expand Addressable Market Opportunity
  • Innovations in Genetic Therapies Generate Demand for Advanced Alpha-1 Antitrypsin Treatments
  • Growth in Biopharmaceutical Sector Accelerates Development of Alpha-1 Antitrypsin Drugs
  • Expanding Applications in Pulmonary and Hepatic Diseases Drive Market Growth
  • Advances in Biomarker Identification Generate New Opportunities for Targeted Therapies
  • Global Trends towards Personalized Medicine Drive Adoption of Customized Treatments
  • Increasing Focus on Rare Disease Treatment Expands Addressable Market Opportunity for Alpha-1 Antitrypsin Drugs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Alpha-1 Antitrypsin Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Alpha-1 Antitrypsin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Prolastin C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Prolastin C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Prolastin C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Glassia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Glassia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Glassia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Aralast NP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Aralast NP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Aralast NP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Zemaira / Respreeza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Zemaira / Respreeza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Zemaira / Respreeza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 17: USA Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 18: USA Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: USA 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Canada Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: Canada 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• JAPAN
  • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 23: Japan Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 24: Japan Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: Japan 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• CHINA
  • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 26: China Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: China Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: China 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• EUROPE
  • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Alpha-1 Antitrypsin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Europe 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• FRANCE
  • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 35: France Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: France Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: France 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• GERMANY
  • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 38: Germany Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Germany Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Germany 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 41: Italy Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Italy Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Italy 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 44: UK Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: UK Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: UK 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Rest of Europe Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Rest of Europe 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Alpha-1 Antitrypsin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Asia-Pacific Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Asia-Pacific 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Rest of World Historic Review for Alpha-1 Antitrypsin Drugs by Drug Type - Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Rest of World 16-Year Perspective for Alpha-1 Antitrypsin Drugs by Drug Type - Percentage Breakdown of Value Sales for Prolastin C, Glassia, Aralast NP and Zemaira / Respreeza for the Years 2014, 2024 & 2030

IV. COMPETITION